Finance

Lists
Why is BCYC down 2.81%?
Dive Deeper
BCYC:NASDAQ
Bicycle Therapeutics PLC
$3.11
-2.81%
(-0.090) 1D
$3.11
0.00% (0.00)
After hours
Closed: Nov 18, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BCYC...
Open
$3.20
High
$3.27
Low
$3.10
Mkt. cap
217.99M
Avg. vol.
418.82K
Volume
0.00
52-wk high
$7.83
52-wk low
$3.07
EPS
-$2.03
Beta
1.59
Shares outstanding
50.66M
No. of employees
288
Open
$3.20
High
$3.27
Low
$3.10
Mkt. cap
217.99M
Avg. vol.
418.82K
Volume
0.00
52-wk high
$7.83
52-wk low
$3.07
EPS
-$2.03
Beta
1.59
Shares outstanding
50.66M
No. of employees
288
News stories
From web sources and news partners
About Bicycle Therapeutics PLC
CEOKevin Lee
Employees288
Founded2009
Headquarters-
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 1 analyst giving stock ratings to BCYC in the past 3 months
Hold
Buy
0
Hold
1
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for BCYC in the last 3 months
Highest
Current $3.11
$5.00 (+60.77%)
Average
$5.00 (+60.77%)
Lowest
$5.00 (+60.77%)
Analyst
Recommendation
Action
Price target
Projected
Date
Leonid Timashev
RBC Capital
Hold
Maintained
$5.00
+60.8%
10/29/2026
Maxwell Skor
Morgan Stanley
Hold
Maintained
-
-
08/17/2026
Jeff Jones
Oppenheimer
Buy
Initiated
$11.00
+253.7%
07/31/2026
Gregory Renza
Truist Financial
Hold
Maintained
$7.00
+125.1%
07/31/2026
Tara Bancroft
TD Cowen
Buy
Maintained
-
-
07/30/2026
Ami Fadia
Needham
Buy
Maintained
$14.00
+350.2%
07/30/2026
Maury Raycroft
Jefferies
Buy
Maintained
$12.00
+285.9%
04/30/2026
Jay Olson
Oppenheimer
Buy
Maintained
$36.00
+1,057.6%
03/18/2026
Reni Benjamin
Citizens JMP
Buy
Maintained
$8.00
+157.2%
03/18/2026
Last report
Oct 29, 2026
Fiscal period
Q3 2026
-$0.15 / -$0.46
+67.30%beat
Revenue / Est. (USD)
34.06M / 12.20M
+179.15%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
47.96M
887.00K
629.00K
34.06M
Cost of goods sold
40.57M
46.96M
41.16M
33.42M
Cost of revenue
40.57M
46.96M
41.16M
33.42M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27.89M
19.41M
14.03M
14.11M
Operating expense
27.89M
19.41M
14.03M
14.11M
Total operating expenses
68.46M
66.37M
55.19M
47.53M
Operating income
-20.51M
-65.48M
-54.56M
-13.48M
Other non operating income
-
-
-
-
EBT including unusual items
-18.89M
-60.65M
-50.24M
-9.31M
EBT excluding unusual items
-14.69M
-60.65M
-50.24M
-9.31M
Income tax expense
1.26M
172.00K
90.00K
1.17M
Effective tax rate
-6.70%
-0.28%
-0.18%
-12.56%
Other operating expenses
-
-
-
-
Net income
-20.15M
-60.82M
-50.33M
-10.48M
Net profit margin
-42.03%
-6,857.38%
-8,002.07%
-30.77%
Earnings per share
-0.29
-0.87
-0.72
-0.15
Interest and investment income
5.88M
4.88M
4.36M
4.21M
Interest expense
-57.00K
-48.00K
-44.00K
-45.00K
Net interest expenses
5.82M
4.83M
4.32M
4.17M
Depreciation and amortization charges
-
-
-
-
EBITDA
-19.17M
-64.35M
-53.49M
-12.40M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps